Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 4/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23953182 | 0.91 | CA12 (0.39) | ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL19156546 | 0.91 | CA12 (0.39) | ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL20820916 | 0.86 | CA12 (0.40) | SMN1; SMN2 | |
| SCHEMBL18744727 | 0.85 | TDO2 (0.40) | TDO2ALOX5APFEN1SMN1; SMN2MMP1 | |
| SCHEMBL12508301 | 0.82 | ALOX5AP (0.46) | TDO2ALOX5APFEN1SMN1; SMN2MMP1 | |
| SCHEMBL19156928 | 0.80 | ALOX5AP (0.46) | TDO2ALOX5APFEN1SMN1; SMN2MMP1 | |
| SCHEMBL19681317 | 0.80 | ALOX5AP (0.46) | TDO2ALOX5APFEN1SMN1; SMN2MMP1 | |
| SCHEMBL19156557 | 0.78 | CA2 (0.40) | TDO2SMN1; SMN2 | |
| SCHEMBL12508138 | 0.76 | ALOX5AP (0.46) | TDO2ALOX5APFEN1SMN1; SMN2MMP1 | |
| SCHEMBL19156975 | 0.76 | MMP1 (0.46) | TDO2ALOX5APFEN1SMN1; SMN2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029979-B2 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use | PIMCO 2664 LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20180037544-A1 | N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE | PIMCO 2664 LIMITED (GB) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037544-A1 | N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE | BRCA1, TPMT, SOST | TDO2 3696/4885ALOX5AP 1477/4885FEN1 4472/4885 |
| US-10029979-B2 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use | BRCA1, TPMT, SOST | TDO2 3683/4885ALOX5AP 1473/4885FEN1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.